What is the appropriate treatment for myxedema (severe hypothyroidism) in adults, including levothyroxine dosing and management of myxedema coma?

Treatment of Myxedema

For severe hypothyroidism (myxedema), initiate levothyroxine with age-appropriate dosing: 50 µg daily for patients over 50-60 years without coronary disease, or 12.5-25 µg daily for those with known coronary heart disease, with careful dose titration every 4-8 weeks based on TSH monitoring. 1

Critical Distinction: Myxedema vs. Myxedema Coma

Standard Myxedema (Severe Hypothyroidism)

Levothyroxine Dosing Strategy:

• Young healthy adults: May start with full replacement dose (~1.6 µg/kg daily) 1
• Patients >50-60 years without cardiac disease: Start with 50 µg daily 1
• Patients with coronary heart disease: Start with 12.5-25 µg daily 1
• Subclinical hypothyroidism: 25-75 µg daily depending on TSH elevation 1

Administration Guidelines:

• Take with water 30-60 minutes before breakfast OR at bedtime 4 hours after last meal 1
• Avoid substances that interfere with absorption (see drug interactions) 1
• For patients unable to take oral medication: Use 70% of oral dose intravenously 1

Monitoring Protocol:

• Check TSH 4-8 weeks after initiation or dose changes 1
• Adjust in 12.5-25 µg increments 1
• Once stable, monitor at 6-month then 12-month intervals 1
• Target TSH within normal reference range (not necessarily low-normal) 1

Myxedema Coma (Life-Threatening Emergency)

Critical FDA Warning: Oral levothyroxine is NOT recommended for myxedema coma due to unpredictable gastrointestinal absorption from poor circulation and hypometabolism. Intravenous thyroid hormone formulations should be used. 2

This represents a fundamental divergence between guideline recommendations and FDA labeling. The FDA explicitly contraindicates oral therapy for myxedema coma 2, while recent research suggests oral therapy may be effective when IV formulations are unavailable 3, 4, 5.

If IV levothyroxine is available (preferred):

• Administer intravenous thyroid hormone products 2
• Consider adding liothyronine for critically ill patients 6

If IV levothyroxine is unavailable (resource-limited settings only): Recent case series suggest oral therapy may be effective despite FDA warnings:

• Loading dose: 300-500 µg oral levothyroxine 3
• Followed by taper over 3-5 days 3
• Alternative: 400 µg loading dose, then 100 µg daily 5
• Mortality remains high but outcomes can be favorable with aggressive supportive care 3, 4

Critical Management Considerations

Adrenal Insufficiency Screening (MANDATORY)

Before initiating levothyroxine, rule out or treat adrenal insufficiency with hydrocortisone. Thyroid hormone increases metabolic clearance of glucocorticoids and can precipitate acute adrenal crisis 1, 2. This is particularly important in:

• Central hypothyroidism patients
• Those at risk for adrenal insufficiency
• Myxedema coma presentations

The FDA lists uncorrected adrenal insufficiency as an absolute contraindication to levothyroxine 2.

Cardiac Monitoring (Essential in Elderly and Cardiac Patients)

Overtreatment risks include:

• Atrial fibrillation (especially elderly) 1
• Angina precipitation 1
• Increased cardiac contractility and arrhythmias 2

If anginal symptoms develop: Reduce dose or withhold for one week, restart at lower dose 2. Monitor closely during surgical procedures in patients with coronary disease 2.

Common Pitfalls to Avoid

1. Starting too high in elderly/cardiac patients: This is the most common error leading to cardiac complications 1, 2

2. Overtreatment: Reported in 20% of treated patients, causing cardiovascular complications, bone loss (especially postmenopausal women), and possible cognitive effects 1

3. Inadequate absorption assessment: Patients on >200 µg/d with persistently elevated TSH are usually non-compliant rather than malabsorbing 1

4. Drug interactions: Many medications interfere with levothyroxine absorption or metabolism—check TSH 4-8 weeks after adding/stopping interacting drugs 1

5. Treating myxedema coma with oral therapy when IV available: This violates FDA guidance and may result in treatment failure 2

Special Populations

Diabetes patients: Levothyroxine may worsen glycemic control—carefully monitor and adjust antidiabetic medications 2

Pregnancy: Requirements increase; monitor every 4 weeks in first 20 weeks 1

Weight changes: Dose based on ideal body weight (lean body mass), not total body weight 1